Triplet Therapeutics, is an early stage start-up biotherapeutics company developing new therapeutic approaches to address triplet repeat disorders such as Huntington’s disease and Myotonic Dystrophy. There are approximately 40 known triple repeat disorders that devastate the lives of people and their families with no known treatment options to date. Triplet aims to change this, developing ground breaking treatments for these patients. The company is led by a highly experienced management team and backed by Atlas Venture.